Population viral load decreases in 'test and treat' study in Uganda
Studies highlight complex questions about how communities will respond to PrEP
Novel TB combination regimen shows potent activity in randomised short-term clinical trial
Once-daily maraviroc plus boosted atazanavir promising at 96 weeks
The paradox of HIV in black MSM in the US – very high infection rates despite no more risky sex and more precautions
International AIDS Conference hears how drugs, sex and HIV interlock
Adolescent antiretroviral options expanding
New antiretrovirals for infants and children still needed
Say it loud: We can end AIDS!
